J Korean Med Assoc.  2015 Dec;58(12):1147-1153. 10.5124/jkma.2015.58.12.1147.

Treatment of uterine leiomyoma: how to choose a therapeutic method?

• Kim YM

• KMID: 2195143
• DOI: http://doi.org/10.5124/jkma.2015.58.12.1147

Abstract

Uterine leiomyomas (myomas or fibroids) are the most common benign pelvic tumors in reproductive aged women occurring in 25% to 40%. They may cause symptoms of heavy or prolonged menstrual bleeding, pelvic pressure symptoms and pain, subfertility, adverse pregnancy outcomes. Therapeutic methods are variable and include expectant management, medical treatment (GnRH agonist, levonorgestrel-releasing intrauterine system, and progesterone receptor modulator), surgical treatment (myomectomy, hysterectomy, and endometrial ablation), myolysis, and uterine artery embolization. Most women who are asymptomatic or have mild symptoms can be followed without intervention. In cases with significant symptoms, the clinicians should understand many factors including age, parity, proximity to menopause, desire for fertility preservation, size, location and number of myomas, severity of symptoms and possibility of malignancy for the choice of treatment modality. The type and timing of the intervention should be individualized after considering and discussing treatment benefit and risk.

Keyword

Myoma; Drug therapy; Uterine myomectomy; Hysterectomy

MeSH Terms

Drug Therapy
Female
Fertility Preservation
Hemorrhage
Humans
Hysterectomy
Infertility
Leiomyoma*
Menopause
Myoma
Parity
Pregnancy
Pregnancy Outcome
Receptors, Progesterone
Uterine Artery Embolization
Uterine Myomectomy
Receptors, Progesterone

Figure

• 

  Figure 1. The FIGO (International Federation of Gynecology and Obstetrics) leiomyoma subclassification system.

Reference

References

1. Leppert PC, Catherino WH, Segars JH. A new hypothesis about the origin of uterine fibroids based on gene expression profiling with microarrays. Am J Obstet Gynecol. 2006; 195:415–420.

2. Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril. 1981; 36:433–445.

3. Rowe MK, Kanouse DE, Mittman BS, Bernstein SJ. Quality of life among women undergoing hysterectomies. Obstet Gynecol. 1999; 93:915–921.

4. Munro MG, Critchley HO, Broder MS, Fraser IS. FIGO Working Group on Menstrual Disorders. FIGO classification system (PALM-COEIN) for causes of abnormal uterine bleeding in nongravid women of reproductive age. Int J Gynaecol Obstet. 2011; 113:3–13.

5. Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril. 2009; 91:1215–1223.

6. Rosati P, Exacoustos C, Mancuso S. Longitudinal evaluation of uterine myoma growth during pregnancy: a sonographic study. J Ultrasound Med. 1992; 11:511–515.

7. Rutkowski P, Spiewankiewicz B, Kosela H, Switaj T, Osuch B, Wiater K, Falkowski S, Mazdziarz A. Sarcoma of the uterus: diagnostic and therapeutic recommendations. Current Gynecologic Oncology. 2013; 11:24–32.

8. Hashimoto K, Azuma C, Kamiura S, Kimura T, Nobunaga T, Kanai T, Sawada M, Noguchi S, Saji F. Clonal determination of uterine leiomyomas by analyzing differential inactivation of the X-chromosome-linked phosphoglycerokinase gene. Gynecol Obstet Invest. 1995; 40:204–208.

9. Ligon AH, Morton CC. Genetics of uterine leiomyomata. Genes Chromosomes Cancer. 2000; 28:235–245.

10. Maekawa R, Sato S, Yamagata Y, Asada H, Tamura I, Lee L, Okada M, Tamura H, Takaki E, Nakai A, Sugino N. Genome-wide DNA methylation analysis reveals a potential mechanism for the pathogenesis and development of uterine leiomyomas. PLoS One. 2013; 8:e66632.

11. Quade BJ, Wang TY, Sornberger K, Dal Cin P, Mutter GL, Morton CC. Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chromosomes Cancer. 2004; 40:97–108.

12. Cook JD, Walker CL. Treatment strategies for uterine leiomyoma: the role of hormonal modulation. Semin Reprod Med. 2004; 22:105–111.

13. Englund K, Blanck A, Gustavsson I, Lundkvist U, Sjoblom P, Norgren A, Lindblom B. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J Clin Endocrinol Metab. 1998; 83:4092–4096.

14. Kawaguchi K, Fujii S, Konishi I, Nanbu Y, Nonogaki H, Mori T. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol. 1989; 160:637–641.

15. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003; 111:1037–1054.

16. Rauk PN, Surti U, Roberts JM, Michalopoulos G. Mitogenic effect of basic fibroblast growth factor and estradiol on cultured human myometrial and leiomyoma cells. Am J Obstet Gynecol. 1995; 173:571–577.

17. Dou Q, Zhao Y, Tarnuzzer RW, Rong H, Williams RS, Schultz GS, Chegini N. Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy. J Clin Endocrinol Metab. 1996; 81:3222–3230.

18. Carlson KJ, Miller BA, Fowler FJ Jr. The Maine Womenʼs Health Study. II. Outcomes of nonsurgical management of leiomyomas, abnormal bleeding, and chronic pelvic pain. Obstet Gynecol. 1994; 83:566–572.

19. Friedman AJ, Hoffman DI, Comite F, Browneller RW, Miller JD. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group. Obstet Gynecol. 1991; 77:720–725.

20. Letterie GS, Coddington CC, Winkel CA, Shawker TH, Loriaux DL, Collins RL. Efficacy of a gonadotropin-releasing hormone agonist in the treatment of uterine leiomyomata: longterm follow-up. Fertil Steril. 1989; 51:951–956.

21. Leather AT, Studd JW, Watson NR, Holland EF. The prevention of bone loss in young women treated with GnRH analogues with “add-back” estrogen therapy. Obstet Gynecol. 1993; 81:104–107.

22. Soysal S, Soysal ME. The efficacy of levonorgestrel-releasing intrauterine device in selected cases of myoma-related menorrhagia: a prospective controlled trial. Gynecol Obstet Invest. 2005; 59:29–35.

23. Donnez J, Tatarchuk TF, Bouchard P, Puscasiu L, Zakharenko NF, Ivanova T, Ugocsai G, Mara M, Jilla MP, Bestel E, Terrill P, Osterloh I, Loumaye E. PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med. 2012; 366:409–420.

24. Donnez J, Tomaszewski J, Vazquez F, Bouchard P, Lemiesz-czuk B, Baro F, Nouri K, Selvaggi L, Sodowski K, Bestel E, Terrill P, Osterloh I, Loumaye E. PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med. 2012; 366:421–432.

25. Donnez J, Vazquez F, Tomaszewski J, Nouri K, Bouchard P, Fauser BC, Barlow DH, Palacios S, Donnez O, Bestel E, Osterloh I, Loumaye E. PEARL III and PEARL III Extension Study Group. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril. 2014; 101:1565–1573.

26. Steinauer J, Pritts EA, Jackson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol. 2004; 103:1331–1336.

27. Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol. 2004; 104:393–406.

28. Dubuisson JB, Fauconnier A, Chapron C, Kreiker G, Norga-ard C. Second look after laparoscopic myomectomy. Hum Reprod. 1998; 13:2102–2106.

29. Mukhopadhaya N, De Silva C, Manyonda IT. Conventional myomectomy. Best Pract Res Clin Obstet Gynaecol. 2008; 22:677–705.

30. Jin C, Hu Y, Chen XC, Zheng FY, Lin F, Zhou K, Chen FD, Gu HZ. Laparoscopic versus open myomectomy: a metaanalysis of randomized controlled trials. Eur J Obstet Gynecol Reprod Biol. 2009; 145:14–21.

31. Luciano AA. Myomectomy. Clin Obstet Gynecol. 2009; 52:362–371.

32. Bedient CE, Magrina JF, Noble BN, Kho RM. Comparison of robotic and laparoscopic myomectomy. Am J Obstet Gynecol. 2009; 201:566.

33. Soto E, Lo Y, Friedman K, Soto C, Nezhat F, Chuang L, Gretz H. Total laparoscopic hysterectomy versus da Vinci robotic hysterectomy: is using the robot beneficial? J Gynecol Oncol. 2011; 22:253–259.

34. Sawin SW, Pilevsky ND, Berlin JA, Barnhart KT. Comparability of perioperative morbidity between abdominal myomectomy and hysterectomy for women with uterine leiomyomas. Am J Obstet Gynecol. 2000; 183:1448–1455.

35. Venturella R, Mocciaro R, Morelli M, Zullo F. Prophylactic salpingectomy does not affect short and long term surgical outcomes when associated to surgery for benign indications. J Minim Invasive Gynecol. 2012; 19:S44.

36. Mints M, Radestad A, Rylander E. Follow up of hysteroscopic surgery for menorrhagia. Acta Obstet Gynecol Scand. 1998; 77:435–438.

37. Funaki K, Fukunishi H, Funaki T, Sawada K, Kaji Y, Maruo T. Magnetic resonance-guided focused ultrasound surgery for uterine fibroids: relationship between the therapeutic effects and signal intensity of preexisting T2-weighted magnetic resonance images. Am J Obstet Gynecol. 2007; 196:184.

38. Salazar GM, Petrozza JC, Walker TG. Transcatheter endo-vascular techniques for management of obstetrical and gynecologic emergencies. Tech Vasc Interv Radiol. 2009; 12:139–147.

39. Hovsepian DM, Siskin GP, Bonn J, Cardella JF, Clark TW, Lampmann LE, Miller DL, Omary RA, Pelage JP, Rajan D, Schwartzberg MS, Towbin RB, Walker WJ, Sacks D. CIRSE and SIR Standards of Practice Committees. Quality improvement guidelines for uterine artery embolization for symptomatic leiomyomata. J Vasc Interv Radiol. 2009; 20(7 Suppl):S193–S199.

40. Berkane N, Moutafoff-Borie C. Impact of previous uterine artery embolization on fertility. Curr Opin Obstet Gynecol. 2010; 22:242–247.